EPIS_B: Q3 saw improved results, US expansion, and strong order growth; 510(k) clearance expected 2025

About this update from Episurf Medical Ab Class B

Episurf improved Q3 results with higher revenues and lower costs, expanded its US sales force, and raised SEK 90m via a rights issue. Regulatory progress continues, with 510(k) clearance for the big toe implant expected in early 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Episurf Medical Ab Class B